Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy. 1983

J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth

We studied the pharmacokinetics of valproic acid (VPA) in 37 children who were taking other antiepileptic drugs. Thirteen children were studied both after initial and while on maintenance valproic acid therapy. Significant differences occurred between initial and maintenance therapy in the mean apparent volume of distribution and in apparent VPA clearance, whereas VPA half-life remained relatively constant. Analysis of data in the 13 children studied on two occasions demonstrated wide intrapatient variability of VPA pharmacokinetics. Children taking VPA together with other antiepileptic medications generally require higher doses of VPA given more frequently.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
April 1985, The Journal of pediatrics,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
July 1979, Archives of neurology,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
September 1988, Clinical pharmacy,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
May 2012, Journal of circadian rhythms,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
January 2017, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
March 1980, The New England journal of medicine,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
October 1995, Clinical pharmacokinetics,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
January 2008, International review of neurobiology,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
April 1991, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses,
J C Cloyd, and R L Kriel, and J H Fischer, and R J Sawchuk, and R M Eggerth
July 2004, Epilepsia,
Copied contents to your clipboard!